Approved indications: Erleada is approved for adults with non-metastatic castration-resistant prostate cancer, and with metastatic castration-sensitive prostate cancer, usually in combination with ongoing androgen-deprivation therapy or after surgical castration.

Off-label uses: Off-label use is limited; in practice, clinicians mainly use apalutamide within or close to its approved prostate cancer settings, sometimes in combination regimens guided by emerging clinical trial data, but other tumor types or non–prostate uses are not established.

Efficacy expectations: Many patients show a PSA decline within weeks to a few months, and trials have demonstrated significant improvements in metastasis-free survival and overall survival compared with androgen-deprivation therapy alone.

Comparison to similar drugs: Erleada is one of several next-generation androgen receptor inhibitors (such as enzalutamide and darolutamide); benefits on disease control and survival are broadly similar, while differences in drug-specific side effects (for example, risk of falls, rash, seizures, or drug interactions) may guide choice in individual patients.

Typical dosing: The recommended adult dose is 240 mg orally once daily (usually four 60‑mg tablets), continued with ongoing androgen-deprivation therapy or after surgical castration, until disease progression or unacceptable toxicity.

How to take: Swallow tablets whole once a day, at about the same time each day, with or without food; do not crush or chew unless specifically instructed by your healthcare provider.

Special instructions: Your doctor may temporarily stop or reduce the dose (to 180 mg or 120 mg once daily) if you develop certain side effects such as severe rash, marked fatigue, or high blood pressure; other medicines you take may also prompt adjustments.

Missed dose: If you miss a dose, take it as soon as you remember on the same day, then return to your regular schedule the next day; if it is almost time for your next dose, skip the missed dose and do not take two doses at once.

Overdose: In case of taking more than the prescribed amount, contact your healthcare provider, poison control center, or seek emergency medical care right away, and bring the medication container with you if possible.

Common side effects: Frequently reported effects include fatigue, high blood pressure, rash, diarrhea, weight loss, joint or muscle pain, hot flashes, falls, and decreased appetite; these often appear in the first weeks to months of treatment and are usually mild to moderate but can sometimes be bothersome.

Serious or rare adverse effects: Serious problems can include fractures, falls with injury, seizures, severe skin reactions, heart-related events (such as ischemic heart disease), and severe hypertension; sudden seizures, chest pain, trouble breathing, signs of stroke, or widespread severe rash require immediate medical attention.

Warnings and precautions: Erleada is not for use in women and can cause harm to an unborn baby; effective contraception is recommended for patients with partners who may become pregnant, and it should not be used during breastfeeding.

Other medical conditions: Caution is needed in patients with a history of seizures, significant heart disease, uncontrolled high blood pressure, or osteoporosis or fracture risk; clinicians often monitor blood pressure, signs of falls or fractures, and laboratory values such as lipids and thyroid function.

Safety compared to similar drugs: Overall safety is comparable to other androgen receptor inhibitors, but each agent has its own profile (for example, Erleada is associated with rash and falls/fractures, while others may have different interaction or neurologic risk patterns), so the choice is individualized.

Reporting side effects and safety updates: Patients are typically advised to report side effects promptly to their oncology team, and adverse events can be reported directly to the FDA’s MedWatch program or the manufacturer; updated safety information is issued through prescribing information revisions and FDA safety communications.

Drug interactions: Erleada can strongly affect liver enzymes that process many medicines; it may lower blood levels and effectiveness of drugs such as certain anticoagulants, antiepileptics, immunosuppressants, HIV medicines, some antidepressants, and many others, so all prescription and over-the-counter drugs should be reviewed by the prescriber.

Supplements, foods, and alcohol: Vitamins and herbal products (especially St. John’s wort and other products that affect liver enzymes) may interact; there are no specific food bans, and it can be taken with or without meals, but heavy alcohol use may worsen side effects like dizziness or falls and strain the liver.

Diagnostic and imaging procedures: No major direct interactions with imaging contrast agents are known, but always tell radiology and other providers that you are taking apalutamide.

Conditions and co-medications requiring caution: Extra care is needed in patients with a history of seizures, significant cardiovascular disease, uncontrolled hypertension, or osteoporosis or high fracture risk, and in those taking other drugs that can lower seizure threshold or affect heart rhythm.

Monitoring needs: Clinicians commonly monitor blood pressure, weight, fall risk, bone health (often with bone-density testing and bone-strengthening measures), and periodic blood tests such as lipids, thyroid function, and other labs, tailored to the individual patient and co-medications.

Q: How long does it take for Erleada to start working?
A: Many patients see a drop in PSA within the first few weeks to a few months, but the goal is long-term control of prostate cancer, which is monitored with regular blood tests and imaging.

Q: Do I need to take Erleada with food?
A: No, Erleada can be taken with or without food, but it should be taken once a day at about the same time each day.

Q: How long will I need to stay on Erleada?
A: Treatment is usually continued as long as it is controlling the cancer and side effects remain manageable, which can be months to years, as decided with your oncologist.

Q: Can women or children take Erleada?
A: Erleada is not approved for women or children, can harm an unborn baby, and is intended for use in adult men with specific types of prostate cancer.

Q: What should I tell my doctor before starting Erleada?
A: Tell your doctor about all your medical conditions (especially heart problems, history of seizures, high blood pressure, or bone problems) and all medicines, vitamins, and herbal supplements you take so they can check for interactions and decide if Erleada is appropriate for you.

Storage: Store Erleada tablets at room temperature (generally 20°C to 25°C / 68°F to 77°F), in the original container, tightly closed, and away from excess heat, moisture, and direct light; keep out of reach of children and pets.

Disposal: Do not flush Erleada down the toilet or pour it down drains; when no longer needed or expired, use a community drug take-back program if available, or follow pharmacist or local waste guidelines for safe disposal in household trash (such as mixing tablets with undesirable material in a sealed container).